Claire Rychlewski is an Editor at Axios Pro. She specializes in health and wellness, supply chain and logistics, and employee benefits, focusing on topics such as logistics technology, consumer health, and workplace health and safety. Claire's insights have been featured in Syncron, Axios, Industry Today Media, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Claire Rychlewski's coverage focuses on business, tech, health, healthcare & pharmaceutical industries. She appears to prioritize articles that include press releases and private sector announcements. Her article titles mostly revolve around mergers and acquisitions in the healthcare industry.
If you are looking to pitch to Claire Rychlewski, consider offering insights into recent M&A activities or significant developments within the healthcare, medtech, or telehealth sectors. Additionally, providing data-backed analysis or exclusive access to notable industry figures could be appealing to her given her frequent citations of data in her articles.
Given that there is no specified geographic focus for Claire’s coverage attributes suggest she takes a broad view of these industries with interest in international as well as domestic market movements and trends.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Dassault Systemes agreed to buy ArisGlobal , an AI drug development software company backed by Nordic Capital, for up to $2 billion.
New Mountain Capital is looking to sell health payments company Machinify, Axios Pro has learned.
The freezing of $1 billion in Medicaid payments to California and Minnesota could spell more trouble for auctions involving behavioral businesses.
Jefferies will advise the seller on the auction.
New Mountain Capital-backed health tech Datavant is working with JPMorgan on a strategic review, Axios Pro has learned.
CapVest Partners-backed Curium agreed to take radiopharma company Lantheus private for up to $8 billion, the companies said Monday.
QuantHealth, an Israeli clinical trial simulation software provider, raised $45 million in Series B funding, CEO Orr Inbar tells Axios Pro exclusively.
Pfizer scrapped two clinical-stage obesity programs, including an oral GLP-1 candidate it inherited when it bought Metsera for $10 billion last year.
Datavant is raising about $2.5 billion in debt in a JPM-run recap process that would restructure its existing facility,
By: Chelsea Naso, Claire Rychlewski
All the afternoon's deals.
